Identification of DNA methylation prognostic signature of acute myelocytic leukemia.

BACKGROUND: The aim of this study is to find the potential survival related DNA methylation signature capable of predicting survival time for acute myelocytic leukemia (AML) patients. METHODS: DNA methylation data were downloaded. DNA methylation signature was identified in the training group, and subsequently validated in an independent validation group. The overall survival of DNA methylation signature was performed. Functional analysis was used to explore the function of corresponding genes of DNA methylation signature. Differentially methylated sites and CpG islands were also identified in poor-risk group. RESULTS: A DNA methylation signature involving 8 DNA methylation sites and 6 genes were identified. Functional analysis showed that protein binding and cytoplasm were the only two enriched Gene Ontology terms. A total of 70 differentially methylated sites and 6 differentially methylated CpG islands were identified in poor-risk group. CONCLUSIONS: The identified survival related DNA methylation signature adds to the prognostic value of AML.

CAT104 silence behaves as a tumor suppressor in human leukemia cells by down regulating miR-182 expression.

BACKGROUND: LncRNAs and miRNAs are found to play crucial roles in the tumorigenesis of acute myeloid leukemia (AML). We aimed to investigate the functions and mechanisms of lncRNA-CAT104 and miR-182 in AML. METHODS: Expression of CAT104, miR-182, and ZEB1 in K562 and HL60 cell lines was respectively or synchronously altered by transfection. Expressions of CAT104, miR-182 and ZEB1 in cell were then analyzed by qRT-PCR. Cell viability, migration, invasion and apoptosis were evaluated by MTT, transwell assays and flow cytometry, respectively. Protein expressions of ZEB1 and factors related with apoptosis and two signal pathways (Wnt/ß-catenin and JNK) were detected by western blot. RESULTS: CAT104 expressed highly in K562 and HL60 cells compared to embryonic kidney cell line HEK293 (P < 0.001). Knockdown of CAT104 inhibited cell viability, migration and invasion, but increased cell apoptosis of K562 and HL60 cells through inhibitionof miR-182 (P < 0.05). miR-182 promoted cell survival, migration and invasion through upregulatingthe expression of ZEB1 (P < 0.05). miR-182 silence deactivated Wnt/ß-catenin and JNK signal pathways by downregulating the expression of ZEB1 in K562 and HL60 cells. CONCLUSION: LncRNA-CAT104 expressed highly in leukemia cells and its silence inhibited cell survival, migration and invasion by downregulating miR-182 expression. miR-182 functioned as an oncogene by upregulating ZEB1 via which miR-182 silence deactivated Wnt/ß-catenin and JNK signal pathways in leukemia cells.

Experience inheritance from famous specialists based on real-world clinical research paradigm of traditional Chinese medicine.

The current modes of experience inheritance from famous specialists in traditional Chinese medicine (TCM) include master and disciple, literature review, clinical-epidemiology-based clinical research observation, and analysis and data mining via computer and database technologies. Each mode has its advantages and disadvantages. However, a scientific and instructive experience inheritance mode has not been developed. The advent of the big data era as well as the formation and practice accumulation of the TCM clinical research paradigm in the real world have provided new perspectives, techniques, and methods for inheriting experience from famous TCM specialists. Through continuous exploration and practice, the research group proposes the innovation research mode based on the real-world TCM clinical research paradigm, which involves the inheritance and innovation of the existing modes. This mode is formulated in line with its own development regularity of TCM and is expected to become the main mode of experience inheritance in the clinical field.